BRAF and thyroid gland carcinoma: The NCI-MATCH trial included patients with BRAF V600E-positive solid tumours (excluding melanoma, thyroid carcinoma and colorectal carcinoma), while the paediatric trial included patients with refractory or recurrent low or high grade glioma.